NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Could Be 24% Undervalued If Its Growth Narrative Holds
Eli Lilly (LLY) is back in focus for investors after its recent share performance, with the stock closing at $1,127.69 and sitting within a large pharmaceutical portfolio that spans cardiometabolic, oncology, immunology, and neuroscience therapies.
See our latest analysis for Eli Lilly.
The recent 0.93% 1 day share price return has added to Eli Lilly’s strong momentum, with a 30 day share price return of 5.91% and a 1 year total shareholder return of 42.83%.
If Eli Lilly’s run has you...